A new approach to protect young hearts from lupus complications

NCT ID NCT07792733

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This study tests whether adding a health navigator to pediatric lupus care teams helps more children receive recommended blood pressure checks and treatments. The trial involves 16 pediatric lupus clinics, which will be randomly assigned to different implementation strategies. Researchers will compare how well each strategy ensures that all patients, especially those in less advantaged neighborhoods, get the care they need. The goal is to find the most effective way to reduce heart risks in children with lupus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Health Navigator Engagement and Team Charter implementation strategies
What this could lead to
If successful, this could identify the best way to help pediatric lupus teams consistently monitor and control blood pressure, potentially reducing long-term heart damage in children with lupus.
What could go wrong
The trial is early and focuses on process improvements rather than direct treatment effects. Results may vary across different clinics, and the strategies might not work equally well in all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2027

An estimate. Start dates often move.

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for EHR Data Collection: * ICD-10-CM or SNOMED-CT diagnosis code for SLE * Completed a pediatric rheumatology outpatient clinical visit at a participating implementation site within 12 months of each data collection timepoint Inclusion Criteria for the Patient Survey Group: * Diagnosis of childhood-onset Systemic Lupus Erythematosus (cSLE) * Must have had a pediatric rheumatology clinical visit at a participating implementation site within 12 months of each data collection timepoint * Age 12 years or older at enrollment Inclusion Criteria for the Caregiver Survey Group: * Individuals at least 18 years of age * Parent or guardian of a child with cSLE who is followed by a care team at a participating site Inclusion Criteria for the Lupus Care Team Member Survey Group: * Individuals at least 18 years of age * Health care team members within a pediatric subspecialty that manages patients with cSLE at a participating site Inclusion Criteria for the Patient Interview Group: * Diagnosis of childhood-onset Systemic Lupus Erythematosus (cSLE) * Completed a clinical visit in the participating site's outpatient rheumatology clinic within the 12 months prior to enrollment * Age 12 years or older at enrollment * Able to provide verbal assent if below age 18 years of age or verbal consent if age 18 years and older. For minors, verbal parental/guardian permission (informed consent) is required. * Have access to a device with audio or audiovisual conferencing capabilities Inclusion Criteria for the Caregiver Interview Group: * Individuals 18 years old or older at enrollment * Parent or guardian of a child with cSLE who is followed by a care team at a participating pediatric rheumatology site and has completed a clinical visit within the 12 months prior to enrollment * Able to provide verbal informed consent prior to the interview * Have access to a device with audio or audiovisual conferencing capabilities Inclusion Criteria for the Lupus Care Team Member Interview Group: * Individuals ages 18 years of age or older at enrollment * Health care team members that are in a pediatric subspecialty clinic that manages patients with cSLE at a participating site * Able to provide verbal informed consent prior to the interview * Have access to a device with audio or audiovisual conferencing capabilities Exclusion Criteria for all Interview Groups: * Unable or without cognitive capacity to participate in an interview, as determined by the investigator(s). * No prospective interview participants will be excluded on the basis of sex, race, ethnicity, or language preference.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood-onset systemic lupus erythematosus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.